The UK and US have finalized a landmark commercial pact that will guarantee zero duties on British pharmaceutical exports entering the US market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has agreed to raise expenditure on pharmaceuticals through the public health system. This move ensures that import taxes on these crucial products will be held at zero for a timeframe of three years.
This deal follows recent statements to hike import taxes on patented pharmaceutical imports, with potential rates mentioned as high as 100%.
"This deal with the Britain reinforces the worldwide climate for cutting-edge drugs and introduces much-needed equity to transatlantic drug exports," a statement noted.
Commercial Significance
Medicines constitute one of the UK's largest export categories to the America, which is by far the largest market for leading British pharmaceutical firms.
Trade data show that in the one-year period to the end of last September, the UK sold pharmaceutical products totaling billions to the US. This value made up a significant portion of British export trade in that span.
"This guarantee secures work, boosts capital expenditure and sets the stage for the UK to establish itself as a worldwide center for medical research," a minister stated.
Specific NHS Changes
The agreement includes several notable changes from the British government:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new treatments to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a aim to raise overall NHS spending on treatments from 0.3 percent of the national economy to 0.6% over the next decade.
- Rebate Cap: The sum drug companies must pay back to the NHS to stay within budget will be capped at 15%. Previously, refunds exceeded twenty percent.
Recent Tensions
The pact comes amid a long-running row between the drug companies and the British authorities over drug pricing and NHS adoption.
This friction were exacerbated by claims that US patients were paying several times more for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several major pharmaceutical investments in the UK have been halted or abandoned, while major expansions have been pledged toward American operations.
One official acknowledged that the NHS must spend more on treatments, noting that its expenditure on drugs had shrunk as a proportion of its resources over the previous ten-year period.
